Volumen: 20 # Number : 2
Publication Date : Mayo - Agosto Year: 2016
Hematopoietic stem cell harvest in poor responders.
Plerixafor : 5 years experience at the Center
for Hematopoietic Stem Cell Transplantation in Uruguay
Authors: Perdomo S, Perdomo A, Lavagna G, Lipschutz J, Rocca A,
Grille S, Isaurralde H, Topolansky L, Zunino J, Stevenazzi M,
Díaz A, Chevalier S, Guadagna R, Díaz L
Abstract: Autologous hematopoietic stem cell transplantation
(HSCT) is a therapeutic alternative for patients with
multiple myeloma and lymphoma. Its success depends
on the number of mobilized progenitor cells,
harvested and infused. Poor stem cell mobilizer patients
fail to obtain an adequate number of cells with
classical stimulation with G-CSF. Treatment with
plerixafor can overcome this difficulty and avoid
re-mobilizations. The aim of our study was to evaluate
and describe the effectiveness and safety of
mobilization with G-CSF and plerixafor with large
volume leukapheresis in 16 poor mobilizer patients.
This strategy achieved suitable values of CD34+ in
peripheral blood in 100% of patients and stem cell
harvest was obtained with a median of 3,85 (range,
2.15-7.14) x 106/ kg of CD34+ cells. The engraftment
was adequate and the median of neutrophils
recovery > 500 / uL was 10 (range, 8-11) days post-
HSCT and platelets recovery > 20,000 / uL was 13
(range, 10-20) days post-HSCT. These results are
similar to those observed in patients with adequate
mobilization.
Key words: plerixafor,
mobilization,
large volume leukapheresis,
engraftment.
Pages : 182 - 188
|
